4th International AIDS Society Conference on HIV Pathogenesis and Treatment


Sydney, Australia - July 22 - 25, 2007

IN VITRO PRODUCTION OF NOVEL HIV-1 SPECIFIC IGA ANTIBODY VARIABLE HEAVY AND LIGHT CHAINS FROM HIV-1 RESISTANT SEX WORKERS FROM NAIROBI, KENYA

IAS Conf HIV Pathog Treat 2007 Jul 22-25;4th: Abstract No. MOPDA03

Sarna C. 1, Ball T.B.1, Gubbins M.J.2, Berry J.D.2, Plummer F.A.2
1University of Manitoba, Department of Medical Microbiology, Winnipeg, Canada, 2National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada

OBJECTIVES: HIV-1-specific mucosal IgA antibodies are important in the development and maintenance of protective immunity against HIV-1. In the Pumwani female sex worker cohort of Nairobi, Kenya, a subset of women remain HIV-1 seronegative despite repeated and prolonged exposure to HIV-1. It has been reported that 76% of these HIV-resistant women produce HIV-1-specific IgA at the genital mucosa; these antibodies may help explain the resistance phenomenon in this cohort. We hypothesize that HIV-1-specific IgA cloned from the genital tract of HIV-1 resistant women of the Pumwani cohort will efficiently recognize the HIV-1 envelope protein gp120, and in its natural form inhibit HIV-1 replication.

METHODS: RNA was isolated from cervical B-cells collected from twelve HIV-1 resistant sex workers and the variable regions of one light and two heavy chain antibody genes were isolated. These novel genes were cloned into an IgA2 expression vector with variable genes from the potent HIV-1-neutralizing monoclonal antibody IgG1b12. Chinese hamster ovary cells were transfected with the constructs and cultured until monoclonal IgA production was detectable by ELISA. The culture supernatants were immunoaffinity purified and gp120 specificity was determined by means of ELISA analysis.

RESULTS: Six antibody constructs, comprising of one b12-like control, three African-b12 hybrids, and two entirely African variants, were successfully produced in vitro. Several samples have been confirmed to bind gp120 with high affinity.

CONCLUSIONS: We have successfully cloned antibody genes from the cervical B-cells of HIV-1-resistant women and produced human monoclonal HIV-1-specific IgA in vitro. This cloning strategy enables the production of large quantities of IgA needed to conduct an in-depth analysis of the protective role of HIV-specific IgA at the genital tract, which is the first step towards designing safe and effective treatments to block HIV-1 transmission. Future directions of this study include viral neutralization and transcytosis assays, and MALDI-TOF mass spectroscopy epitope mapping.

Acrobat ReaderDownload PDF of this abstract.

Power Point PresentationDownload Power Point Presentation.

2007-07-22
MOPDA03
Models for Mucosal Immunity and Transmission

Copyright © 2007 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.